TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04699435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the Control group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PreOx_3min
Description: Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group PreOx_3min.~All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 3-minute pre-oxygenation for the PreOx_3min group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PreOx_6min
Description: Patients with a BMI between 30 kg / m² and 40 kg / m² are distributed according to a random allocation in the group PreOx_6min.~All patients are installed with a 30 ° proclive and have pre-oxygenation (FiO2 = 1) with a face mask. At the end of the 6-minute pre-oxygenation for the PreOx_3min group, the values of ORI, SpO2, mean arterial pressure and heart rate are recorded.
Study: NCT05701514

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elective surgical resection of CPAM between 6 and 9 months of age
Description: Surgical resection of the CPAM between 6 and 9 months of age
Study: NCT04692597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoenix Thera-Lase System
Description: Low level laser therapy (LLLT) using Phoenix Thera-lase device (74 Watts, 1275 nm wavelength) for 6 minutes per affected hand.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM Phoenix Thera-Lase System
Description: Sham LLLT using the Phoenix Thera-lase device with the guide light on but without emitting laser photons for 6 minutes per affected hand.
Study: NCT05555290

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PT027
Description: When administered PT027, participants will receive 2 actuations of albuterol- budesonide per dose administered as oral inhalations.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PT027
Description: When administered PT027, participants will receive 2 actuations of albuterol- budesonide per dose administered as oral inhalations.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PT007
Description: When administered PT007, participants will receive 2 actuations of albuterol administered as oral inhalations.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PT007
Description: When administered PT007, participants will receive 2 actuations of albuterol administered as oral inhalations.
Study: NCT05863416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion
Description: Intraoperative dexmedetomidine infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine infusion
Description: Intraoperative dexmedetomidine infusion
Study: NCT04791072

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Breathing exercise training Use of incentive spirometry Aerobic exercise training Strengthening exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Breathing exercise training Use of incentive spirometry Aerobic exercise training Strengthening exercises
Study: NCT06162832

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Allograft and rHPDGF-BB
Description: At this intervention the periodontal defect will be treated with allograft and rHPDGF-BB (GEM21)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Allograft and rHPDGF-BB
Description: At this intervention the periodontal defect will be treated with allograft and rHPDGF-BB (GEM21)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Allograft and Saline solution
Description: This will be used as the control group

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Allograft and Saline solution
Description: This will be used as the control group
Study: NCT04113759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Rehabilitative Therapy
Description: BFR cuffs placed at the proximal thigh, just inferior to the greater trochanter.~Inflation time not to exceed 20 minutes. One BFR session per treatment. BFR exercise dosage: 4 sets of the following repetitions 30, 15, 15, 15, 30 second rest between sets, 1 min rest between exercises.~Progress exercise if pain \<2/10 on VAS and RPE \<5 on 0-10 scale. (Heerey et al), and no break down in form.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sham BFR Rehabilitative Therapy
Description: The schedule, type of exercises, repetition ranges, and other physical therapy interventions will be the same as the BFR experimental group - however a non-occlusive pressure will be applied with the cuff in the control group.
Study: NCT04737252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sage (formerly known as COMPASS)
Description: Sage is a remote 12 session intervention for couples wherein one individual has Borderline Personality Disorder (BPD) and engages in self-injury thoughts and behaviours. The intervention consists of elements of Cognitive Behavioural Conjoint Therapy (CBCT) and has been adapted for this population. Couples will meet remotely with a clinician (registered psychologists and/or graduate level clinicians) for 8-12 sessions via Zoom Healthcare. The primary outcomes are self-injury thoughts and behaviours (as measured by the Suicide Attempt and Self-Injury Interview-modified, and the Beck Scale for Suicidal Ideation and ecological momentary assessment) and borderline personality disorder symptoms (as measured by the Borderline Symptom List-23).
Study: NCT05296668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cuffed ETT (Microcuff®, Halyard Health Inc., Atlanta, GA, USA)
Description: (group C) to receive a cuffed ETT for airway management.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cuffed ETT (Microcuff®, Halyard Health Inc., Atlanta, GA, USA)
Description: (group C) to receive a cuffed ETT for airway management.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uncuffed ETT group
Description: (group U) to receive an uncuffed ETT for airway management.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncuffed ETT group
Description: (group U) to receive an uncuffed ETT for airway management.
Study: NCT06241898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-1709
Description: Subjects participating in Phase Ia study may continue to receive study treatment as long as they continue to show clinical benefit as judged by the investigator, until disease progression or intolerable toxicity, withdrawal of consent, death, or termination of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-1709
Description: Subjects participating in Phase Ia study may continue to receive study treatment as long as they continue to show clinical benefit as judged by the investigator, until disease progression or intolerable toxicity, withdrawal of consent, death, or termination of the study.
Study: NCT06496919

Intervention type: DRUG
Intervention: Recombinant Mutant Human Tumor Necrosis Factor
Description: The patients who received rmhTNF intraperitoneal perfusion (intraperitoneal surgical field flushing perfusion or intraperitoneal thermal perfusion chemotherapy)

Intervention type: DRUG
Intervention: Recombinant Mutant Human Tumor Necrosis Factor
Description: The patients who received rmhTNF intraperitoneal perfusion (intraperitoneal surgical field flushing perfusion or intraperitoneal thermal perfusion chemotherapy)
Study: NCT04899739

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echoendoscopy
Description: Peripancreatic lymph nodes and at a distance from the pancreas assessment by endoscopic ultrasound, elastography an doppler to record their anatomical location and characteristics. All lymph nodes suspected of metastatic disease will be marked with sterile black ink.
Study: NCT05902299

Intervention type: DRUG
Intervention: Antibiotic
Description: Evaluate the choice of antibiotic therapy prescribed for P. aeruginosa ou S. aureus infection
Study: NCT05606172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Intervention for PTSD (PCIP) Youth aged 6 -11
Description: This treatment ranges from 1-4 sessions which last 50 minutes per session. The first session will cover psychoeducation about PTSD symptoms in children that can be delivered to the parent or both the parent and child. The first session will also teach the parent and child a breathing technique to combat the physiological impact of PTSD in children. The subsequent sessions will be tailored to meet the needs of the child's most distressing PTSD symptom cluster including hyper arousal, negative changes in cognition and mood, avoidance, re-experiencing. Each session contains coping skills that the parent and child can learn together. There is also material for parents to address behavior problems in youth. This treatment will be delivered via telehealth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Treatment as Usual
Description: Will receive treatment as usual at local clinic and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
Study: NCT04817488

Intervention type: OTHER
Intervention: Prehospital emergency ultrasound with tele-supervision
Description: Prehospital emergency ultrasound with tele-supervision in patients with acute dyspnoea

Intervention type: OTHER
Intervention: Prehospital emergency ultrasound without tele-supervision
Description: Prehospital emergency ultrasound without tele-supervision in patients with acute dyspnoea
Study: NCT05353855

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04687046

Intervention type: DEVICE
Intervention: JUVÉDERM VOLUX®
Description: JUVÉDERM VOLUX® injectable gel

Intervention type: DEVICE
Intervention: JUVÉDERM VOLUX®
Description: JUVÉDERM VOLUX® injectable gel
Study: NCT05805800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5HT3RA+Olanzapine
Description: Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.~On day 1-4, Olanzapine is delivered orally after dinner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5HT3RA+Olanzapine+Dexamethasone
Description: Using one of the 5-HT3 receptor antagonists within 30 minutes before cisplatin/adriamycin/cyclophosphamide.~On day 1-4, Olanzapine is delivered orally after dinner. On first day, dexamethasone is given orally within 30 minutes before cisplatin/adriamycin/cyclophosphamide administered.~Other Names:~Acidocont; Deronil; Dexacortal; Desameton; Fluprednisolone; (11β，16α-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
Study: NCT06468878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Intervention Plus Music Induction
Description: VR exposure for acrophobia with background music.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Intervention With No Music Induction
Description: VR exposure for acrophobia with no background music.
Study: NCT04862923

Intervention type: DRUG
Intervention: Oral semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to treat the participant with a given product is independent of the decision to include him/her in the study.
Study: NCT04838457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol and CVD Management and Engagement through Telehealth and mHealth (ACME-TM)
Description: Participants will obtain 4 sessions of telehealth cognitive behavioral therapy (CBT) focused on reducing alcohol misuse. Participants will receive a 5th telehealth coaching call to develop a plan for ensuing treatment regarding their elevated cardiovascular risk factors. Participants will then receive daily texts for one month aimed at helping them decrease these cardiovascular risk factors.
Study: NCT04124341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefrontal Cortical Stimulation (PCS)
Description: Prior to surgery, subjects will undergo a high resolution structural scan to identify anatomical landmarks for rostral anterior and lateral prefrontal cortex. Following identification of target areas, PCS quad leads will be projected over the anterior and lateral prefrontal cortex. Subjects will be kept in the hospital for a minimum of 72 hours for observation during which the investigators will obtain a high resolution spiral CT scan without contrast to confirm lead placements post-operatively and rule out any intra-cranial bleeds. Patients will receive analgesics which they may continue as an outpatient on as needed basis. During this 2-3 weeks recovery period, the attention to pain control and mood is critical. The research team will contact patients at least twice per week to check on their status.
Study: NCT05478135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVIFY Oncology Hub
Description: NAVIFY Oncology Hub is a platform that aggregates and organizes disparate data into an intuitive, longitudinal view of the patient's cancer care journey. The platform is designed to optimize and support oncology workflows and decision-making by providing quick access to the most relevant data in one place, so that providers can make decisions more efficiently and collaborate more seamlessly.
Study: NCT05596890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: 260mg/m2, ivdrip, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60mg/m2, ivdrip, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC=4-6, ivdrip, d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg, ivdrip, d1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: VMAT or IMRT
Description: 15Gy/5F (d43-d50, d57-d64), 5 times a week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Minimally-invasive or open McKeown and Ivor-Lewis esophagectomy
Study: NCT06302452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adopting Comprehensive Training for FireArm Safety in Trauma Centers
Description: Firearm access screening, brief firearm safe storage intervention, and referral to community and preventive health resources
Study: NCT05231733

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPX-101
Description: Subjects will receive SPX-101 on Day 1 of the first cycle, and will be evaluated for DLTs in the following 3 weeks. After the first cycle, subjects will continue treatment at dosing intervals as determined by safety and PK results. All patients will continue treatment until disease progression, development of unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at patient discretion (maximum duration: 2 years).
Study: NCT05025800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD47 Antagonist ALX148
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT06460844

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RTx-015
Description: Intravitreal injection using gene therapy to deliver an optogenetic gene to the eye. Cells in the retina use this Optogenetic gene to make a protein that responds to light.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RTx-015
Description: Intravitreal injection using gene therapy to deliver an optogenetic gene to the eye. Cells in the retina use this Optogenetic gene to make a protein that responds to light.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RTx-015
Description: Intravitreal injection using gene therapy to deliver an optogenetic gene to the eye. Cells in the retina use this Optogenetic gene to make a protein that responds to light.
Study: NCT06216574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Intervention
Description: Receive access to SHINE modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Intervention
Description: Receive access to SHINE modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Intervention
Description: Receive access to SHINE modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Intervention
Description: Receive access to SHINE modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Intervention
Description: Receive access to SHINE modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Intervention
Description: Receive access to SHINE modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Intervention
Description: Receive access to SHINE modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Intervention
Description: Receive access to SHINE modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Intervention
Description: Receive access to SHINE modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Intervention
Description: Receive access to SHINE modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Intervention
Description: Receive access to SHINE modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Intervention
Description: Receive access to SHINE modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Intervention
Description: Receive access to SHINE modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Intervention
Description: Receive access to SHINE modules
Study: NCT06412497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-Transplant G-CSF
Description: Beginning on day +5, patients will receive G-CSF SQ or IV 5 micrograms/kg once daily until post-nadir ANC \> 1500/μL for 3 consecutive days or \>3000/μL for 1 day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will begin on day +5 at an initial dose of 0.03 mg/kg/day IV via continuous infusion. Goal trough levels will be 10-15 ug/mL until day +14 posttransplant, then decreased to a goal of 5-10 ng/mL thereafter. In the absence of GvHD, tacrolimus will discontinue at day +180 without a taper.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will begin on day +5 at an initial dose of 0.03 mg/kg/day IV via continuous infusion. Goal trough levels will be 10-15 ug/mL until day +14 posttransplant, then decreased to a goal of 5-10 ng/mL thereafter. In the absence of GvHD, tacrolimus will discontinue at day +180 without a taper.
Study: NCT06216574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Intervention
Description: Receive access to SHINE modules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based Intervention
Description: Receive access to SHINE modules
Study: NCT05966480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESK-001
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study: NCT05409066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral Capsules
Study: NCT04579523

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HCT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspirate
Study: NCT05409066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Oral Capsules
Study: NCT04579523

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo chest x-rays

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo chest x-rays